Exubera Inhaled Insulin User Fee Deadline Is January 2006
This article was originally published in The Pink Sheet Daily
Executive Summary
Pfizer and Sanofi-Aventis filed the Exubera NDA March 1; an early 2006 approval is based on a standard 10-month review. The companies expected to submit an NDA in 2001, but were delayed by pulmonary safety questions.
You may also be interested in...
Pfizer's Exubera Inhaled Insulin To Be Reviewed By Endocrine Committee Sept. 8
Inhalation powder will be evaluated for diabetes mellitus in adults by FDA's Endocrinologic & Metabolic Drugs Advisory Committee. Developed in conjunction with Sanofi-Aventis, Exubera would be first inhaled insulin product.
Pfizer's Exubera Inhaled Insulin To Be Reviewed By Endocrine Committee Sept. 8
Inhalation powder will be evaluated for diabetes mellitus in adults by FDA's Endocrinologic & Metabolic Drugs Advisory Committee. Developed in conjunction with Sanofi-Aventis, Exubera would be first inhaled insulin product.
Tysabri Could Return In Fall; Marketing Suspended By Biogen Idec And Elan
One fatal, confirmed case of progressive multifocal leukoencephalopathy and one suspected case prompt withdrawal of multiple sclerosis product; risk/benefit ratio needs to be reestablished, companies say. Return to market would not be unprecedented, but Tysabri’s withdrawal sharpens focus on FDA's drug safety oversight.